Sometimes, being the “squeaky wheel” is the only way to make a positive change.
Site Search
All my life I wanted an answer to why I was so sick. Then I got it, in the form of a CF diagnosis.
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
When our son was diagnosed with CF, the clinic director sat with me for hours answering my questions. Since that day, I have wanted to bottle up his advice and become a voice of encouragement for new CF parents.
Dr. Skach discusses the latest advances in CF research and exciting new approaches to address the underlying cause of the disease.
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.
The purpose of the Screening Improvement Program mechanism is to catalyze efforts aimed at improving the screening system used for early diagnosis.
The Cystic Fibrosis Foundation is requesting applications with a Letter of Intent for innovative, multi-site quality improvement projects that aim to test tools and processes facilitating remote cystic fibrosis care delivery.
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2